Amgen has initiated new litigation over the patent provisions of the BPCIA, this time against Hospira in the U.S. District Court for the District of Delaware, regarding Hospira’s biosimilar…
Amgen has initiated new litigation over the patent provisions of the BPCIA, this time against Hospira in the U.S. District Court for the District of Delaware, regarding Hospira’s biosimilar…
Complaint Hospira’s Motion to Dismiss Count I and Count II Amended Complaint Hospira’s Letter to the Court re: Hospira’s Motion to Dismiss Hospira’s Motion to Dismiss Count…
As we reported in a previous post, the parties in Janssen v. Celltrion–a BPCIA-related case pending in the District of Massachusetts—are currently litigating whether Celltrion’s…
In their reply briefs, Amgen and Sandoz further sharpened their arguments in opposition to the en banc review sought by the other. Sandoz continued to emphasize that the text of…
Amgen and Sandoz have filed responses to each other’s petitions for rehearing en banc in Amgen v. Sandoz. Amgen’s response to Sandoz’s petition is available here, and Sandoz’s…
Amgen and Sandoz have filed a joint motion to lift the stay of proceedings on Amgen’s patent infringement claims and Sandoz’s related counterclaims in the U.S. District Court for the…
Hospira, Inc., Celltrion Healthcare Co., Ltd., and Celltrion Inc. (jointly) and the Biosimilars Council filed amicus briefs today in support of Sandoz’s petition for rehearing en banc in Amgen v….
Following the end of the injunction imposed by the Federal Circuit’s July 21st opinion in Amgen v. Sandoz, Sandoz today launched its biosimilar product Zarxio–the first product to be…
The Federal Circuit has denied Amgen’s Emergency motion for a temporary injunction pending en banc consideration and review in Amgen v. Sandoz. Per the Federal Circuit’s July…
Sandoz has filed its opposition to Amgen’s motion seeking an “emergency” injunction from the Federal Circuit to extend the injunction blocking Sandoz from launching its Zarxio biosimilar…